Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. Dec 2001; 85(12): 1878–1882.
PMCID: PMC2363999

Expression of the hypermethylated in cancer gene (HIC-1) is associated with good outcome in human breast cancer

Abstract

A new cancer gene, HIC-1 (Hypermethylated in Cancer) telomeric to p53 on chromosome 17p may be of clinical importance in sporadic breast cancer. Regional DNA hypermethylation of 17p13.3 resulting in suppression of gene expression has been shown to precede 17p structural changes in human carcinogenesis. In addition, loss of heterozygosity studies have suggested clinically significant involvement of a gene on 17p13.3 associated with poor prognosis in breast cancer. Using RT-PCR analysis, we demonstrate that the MCF7 (wild type p53) cell line expressed HIC-1 transcripts but the MDAMB231 (mutant p53) cell line did not, suggesting loss of HIC-1 expression and p53 malfunction may be synergistic events in sporadic breast cancer. HIC-1 expression was examined using RT-PCR on RNA extracted from 50 primary untreated, human breast cancers and was detected in only 7/50 (14%) cancers. All seven patients with HIC-1 expression were alive without disease recurrence after 8 years follow-up and 5/7 had detectable p53 wild type mRNA expression. This suggests that retained HIC-1 expression may offer a survival advantage. However the seven cancers had 17p13.3 loss of heterozygosity (LOH; four patients), a feature previously associated with poor prognosis, or were homozygous (three patients) suggesting there may be two genes at 17p13.3 involved in breast carcinogenesis. Using a demethylating drug 5-aza-2′-deoxycytidine (DeoxyC), HIC-1 expression was restored in the MDAMB231 cells, also suggesting restoration of HIC-1 function by reversing HIC-1 hypermethylation may offer a therapeutic avenue in breast cancer. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: HIC-1, hypermethylation, p53, prognosis, breast cancer

Full Text

The Full Text of this article is available as a PDF (75K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Aldaz CM, Chen T, Sahin A, Cunningham J, Bondy M. Comparative allelotype of in situ and invasive human breast cancer: high frequency of microsatellite instability in lobular breast carcinomas. Cancer Res. 1995 Sep 15;55(18):3976–3981. [PubMed]
  • Carter MG, Johns MA, Zeng X, Zhou L, Zink MC, Mankowski JL, Donovan DM, Baylin SB. Mice deficient in the candidate tumor suppressor gene Hic1 exhibit developmental defects of structures affected in the Miller-Dieker syndrome. Hum Mol Genet. 2000 Feb 12;9(3):413–419. [PubMed]
  • Casey G, Plummer S, Hoeltge G, Scanlon D, Fasching C, Stanbridge EJ. Functional evidence for a breast cancer growth suppressor gene on chromosome 17. Hum Mol Genet. 1993 Nov;2(11):1921–1927. [PubMed]
  • Coles C, Thompson AM, Elder PA, Cohen BB, Mackenzie IM, Cranston G, Chetty U, Mackay J, Macdonald M, Nakamura Y, et al. Evidence implicating at least two genes on chromosome 17p in breast carcinogenesis. Lancet. 1990 Sep 29;336(8718):761–763. [PubMed]
  • Cornelis RS, van Vliet M, Vos CB, Cleton-Jansen AM, van de Vijver MJ, Peterse JL, Khan PM, Børresen AL, Cornelisse CJ, Devilee P. Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations. Cancer Res. 1994 Aug 1;54(15):4200–4206. [PubMed]
  • Cross SH, Charlton JA, Nan X, Bird AP. Purification of CpG islands using a methylated DNA binding column. Nat Genet. 1994 Mar;6(3):236–244. [PubMed]
  • Deltour S, Guerardel C, Stehelin D, Leprince D. The carboxy-terminal end of the candidate tumor suppressor gene HIC-1 is phylogenetically conserved. Biochim Biophys Acta. 1998 Nov 26;1443(1-2):230–232. [PubMed]
  • Fujii H, Biel MA, Zhou W, Weitzman SA, Baylin SB, Gabrielson E. Methylation of the HIC-1 candidate tumor suppressor gene in human breast cancer. Oncogene. 1998 Apr 23;16(16):2159–2164. [PubMed]
  • Guerardel C, Deltour S, Leprince D. Evolutionary divergence in the broad complex, tramtrack and bric à brac/poxviruses and zinc finger domain from the candidate tumor suppressor gene hypermethylated in cancer. FEBS Lett. 1999 May 28;451(3):253–256. [PubMed]
  • Issa JP, Baylin SB, Herman JG. DNA methylation changes in hematologic malignancies: biologic and clinical implications. Leukemia. 1997 Mar;11 (Suppl 1):S7–11. [PubMed]
  • Li Q, Jedlicka A, Ahuja N, Gibbons MC, Baylin SB, Burger PC, Issa JP. Concordant methylation of the ER and N33 genes in glioblastoma multiforme. Oncogene. 1998 Jun 18;16(24):3197–3202. [PubMed]
  • Liscia DS, Morizio R, Venesio T, Palenzona C, Donadio M, Callahan R. Prognostic significance of loss of heterozygosity at loci on chromosome 17p13.3-ter in sporadic breast cancer is evidence for a putative tumour suppressor gene. Br J Cancer. 1999 May;80(5-6):821–826. [PMC free article] [PubMed]
  • Makos M, Nelkin BD, Reiter RE, Gnarra JR, Brooks J, Isaacs W, Linehan M, Baylin SB. Regional DNA hypermethylation at D17S5 precedes 17p structural changes in the progression of renal tumors. Cancer Res. 1993 Jun 15;53(12):2719–2722. [PubMed]
  • Wales MM, Biel MA, el Deiry W, Nelkin BD, Issa JP, Cavenee WK, Kuerbitz SJ, Baylin SB. p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat Med. 1995 Jun;1(6):570–577. [PubMed]
  • Nagai MA, Medeiros AC, Brentani MM, Brentani RR, Marques LA, Mazoyer S, Mulligan LM. Five distinct deleted regions on chromosome 17 defining different subsets of human primary breast tumors. Oncology. 1995 Nov-Dec;52(6):448–453. [PubMed]
  • O'Neill M, Campbell SJ, Save V, Thompson AM, Hall PA. An immunochemical analysis of mdm2 expression in human breast cancer and the identification of a growth-regulated cross-reacting species p170. J Pathol. 1998 Nov;186(3):254–261. [PubMed]
  • Phelan CM, Borg A, Cuny M, Crichton DN, Baldersson T, Andersen TI, Caligo MA, Lidereau R, Lindblom A, Seitz S, et al. Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters. Cancer Res. 1998 Mar 1;58(5):1004–1012. [PubMed]
  • Phillips NJ, Ziegler MR, Radford DM, Fair KL, Steinbrueck T, Xynos FP, Donis-Keller H. Allelic deletion on chromosome 17p13.3 in early ovarian cancer. Cancer Res. 1996 Feb 1;56(3):606–611. [PubMed]
  • Stack M, Jones D, White G, Liscia DS, Venesio T, Casey G, Crichton D, Varley J, Mitchell E, Heighway J, et al. Detailed mapping and loss of heterozygosity analysis suggests a suppressor locus involved in sporadic breast cancer within a distal region of chromosome band 17p13.3. Hum Mol Genet. 1995 Nov;4(11):2047–2055. [PubMed]
  • Steele RJ, Thompson AM, Hall PA, Lane DP. The p53 tumour suppressor gene. Br J Surg. 1998 Nov;85(11):1460–1467. [PubMed]
  • Theile M, Hartmann S, Scherthan H, Arnold W, Deppert W, Frege R, Glaab F, Haensch W, Scherneck S. Suppression of tumorigenicity of breast cancer cells by transfer of human chromosome 17 does not require transferred BRCA1 and p53 genes. Oncogene. 1995 Feb 2;10(3):439–447. [PubMed]
  • Thompson AM, Steel CM, Chetty U, Hawkins RA, Miller WR, Carter DC, Forrest AP, Evans HJ. p53 gene mRNA expression and chromosome 17p allele loss in breast cancer. Br J Cancer. 1990 Jan;61(1):74–78. [PMC free article] [PubMed]
  • Thompson AM, Anderson TJ, Condie A, Prosser J, Chetty U, Carter DC, Evans HJ, Steel CM. p53 allele losses, mutations and expression in breast cancer and their relationship to clinico-pathological parameters. Int J Cancer. 1992 Feb 20;50(4):528–532. [PubMed]
  • Thompson AM, Crichton DN, Elton RA, Clay MF, Chetty U, Steel CM. Allelic imbalance at chromosome 17p13.3 (YNZ22) in breast cancer is independent of p53 mutation or p53 overexpression and is associated with poor prognosis at medium-term follow-up. Br J Cancer. 1998 Mar;77(5):797–800. [PMC free article] [PubMed]
  • Ziyaie D, Hupp TR, Thompson AM. P53 and breast cancer. Breast. 2000 Oct;9(5):239–246. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Compound
    Compound
    PubChem Compound links
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...